GLP-1 & Weight.
Incretin and metabolic-axis compounds studied for appetite and glucose regulation.
Amycretin / MariTide / Pemvidutide
Three next-generation obesity compounds — Amycretin (Novo), MariTide (Amgen) and Pemvidutide (Altimmune) — by mechanism…
AOD-9604
AOD-9604 is a modified fragment of the C-terminus of human growth hormone (amino acids 176…
Adipotide
Adipotide (CKGGRAKDC-GG-D(KLAKLAK)2) is a proapoptotic peptide that selectively induces ap…
Cagrilintide
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk, designed for once…
CagriSema
CagriSema is Novo Nordisk's once-weekly combination of cagrilintide and semaglutide; REDEFINE 1 showed 22.7% weight loss…
Liraglutide
Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk and approved as Victoza …
Mazdutide
Mazdutide (IBI362) is a dual GLP-1 receptor and glucagon receptor agonist under clinical d…
Retatrutide
GLP-1 + GIP + glucagon receptor agonism simultaneously. Retatrutide is the most potent wei…
Semaglutide
Semaglutide is the GLP-1 receptor agonist approved as Ozempic (diabetes) and Wegovy (obesi…
Survodutide
Survodutide (BI 456906) is a dual GLP-1 receptor and glucagon receptor agonist developed b…
Tesofensine
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, dopamine, noradrenaline) …
Tirzepatide
Tirzepatide is the dual GLP-1/GIP receptor agonist approved by the FDA as Mounjaro (diabet…
VK2735
VK2735 is Viking Therapeutics' dual GLP-1/GIP receptor agonist for obesity, in subcutaneous and oral forms — investigational…
Orforglipron
Orforglipron (Foundayo) is Eli Lilly's once-daily oral GLP-1 receptor agonist — the first non-peptide small molecule in its class, taken…
CT-388
CT-388 (also called RO7690479 or enicepatide) is Roche's investigational once-weekly dual GLP-1/GIP receptor agonist for obesity, acquired…
Dapiglutide
Dapiglutide (ZP7570) is Zealand Pharma's investigational dual GLP-1/GLP-2 receptor agonist, studied for short bowel syndrome and obesity —…
Ecnoglutide
Ecnoglutide (XW003) is Sciwind Biosciences' cAMP-biased GLP-1 receptor agonist, in Phase 3 development in China for type 2 diabetes and…
Efinopegdutide
Efinopegdutide (MK-6024) is Merck's investigational dual GLP-1/glucagon receptor agonist, developed primarily for metabolic liver disease…
Pramlintide
Pramlintide is a synthetic analogue of amylin, the pancreatic hormone that slows gastric emptying and blunts post-meal glucagon — the same…
ZP6590
ZP6590 is Zealand Pharma's investigational long-acting GIP receptor agonist, designed not as a standalone obesity drug but as a…
Exenatide
Exenatide is the original GLP-1 receptor agonist, derived from a peptide found in Gila monster venom — the foundation compound that opened…
Dulaglutide
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist fused to a modified antibody fragment (Fc region), which extends its…
Glucagon
Glucagon is insulin's counter-hormone — the emergency rescue treatment for severe hypoglycemia, and increasingly a research target as a…